在阿尔茨海默氏症治疗中目标,试验和苦难
Ruchita Gharat1, Gargi Dixit1, Mihir Khambete2
1SVKM's Dr. Bhanuben Nanavati College of Pharmacy, VM Road, Vile Parle (West), Mumbai, 400056, Maharashtra, India.
European journal of pharmacology
|December 2, 2023
概括
开发有效的阿尔茨海默氏病 (AD) 治疗需要了解超越当前症状缓解的新目标. 从过去的临床试验中吸取的教训对于推进AD的疾病修饰疗法至关重要.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 目前的AD治疗依赖于胆酶抑制剂,仅提供症状缓解.
- 对于阿尔茨海默氏症的疾病修饰疗法,存在重大未满足的需求.
研究的目的:
- 审查阿尔茨海默病的各种治疗点.
- 分析从AD治疗药物的临床评估中学到的经验教训.
- 强调了解阿尔茨海默氏症大脑病理学对药物开发的重要性.
主要方法:
- 关于阿尔茨海默氏症病理学的文献综述.
- 对AD治疗药物的临床试验结果的分析.
- 检查治疗目标及其临床翻译.
主要成果:
- 许多临床试验 (超过170) 正在研究疾病修饰和认知增强.
- 在AD药物开发中的挑战包括缺乏治疗转化和不良事件.
- 了解调节阿尔茨海默氏症大脑病理学的影响是关键.
结论:
- 目前对阿尔茨海默病的治疗策略有限.
- 过去的临床试验失败为未来的药物开发提供了关键的见解.
- 进一步研究新的治疗点对于阻止AD进展至关重要.
相关概念视频
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
128
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
128


